Trials / Conditions / Renal Pelvis Cancer

Renal Pelvis Cancer

14 registered clinical trials studyying Renal Pelvis Cancer — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069	Eli Lilly and Company	Phase 1
Not Yet Recruiting	Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients NCT06469229	Changhai Hospital	—
Not Yet Recruiting	Urine DNA Methylation Detection for Hematuria Evaluation NCT06427993	Changhai Hospital	—
Active Not Recruiting	A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors NCT06238479	Eli Lilly and Company	Phase 1
Recruiting	Radical Radiotherapy Versus Radical Surgery for UTUC NCT06652009	Peking University First Hospital	—
Completed	Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors NCT03662204	Exact Sciences Corporation	—
Completed	Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer NCT02300610	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
Completed	A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function NCT02665039	Dr Anders Ullén	Phase 2
Completed	Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothe NCT01844947	Dr Anders Ullén	Phase 1
Completed	Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignanci NCT01182168	Memorial Sloan Kettering Cancer Center	Phase 1
Completed	Cancer in Patients With Gabapentin (GPRD) NCT01236053	GlaxoSmithKline	—
Completed	Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) NCT01138124	GlaxoSmithKline	—
Active Not Recruiting	A Genotype-Phenotype Urothelial Cancer Registry NCT00902590	Memorial Sloan Kettering Cancer Center	—
Completed	A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer NCT00661609	AstraZeneca	Phase 2